FINNENCE ▪ THE WIRE FILE
THE WIRE · № 55432
News■ Unclear/unknown
What Oura’s IPO could mean for digital health
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-09-29 10:00 UTC
LAST UPDATE2026-09-29 10:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Analysis of what an Oura IPO would mean for digital health is speculative given the IPO is now delayed.
Digital health IPO interest remains tentative
CATALYST TO WATCH
Any future Oura listing decision
MAIN RISK
Speculative with no confirmed transaction
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Smart Ring Maker Oura Delays IPO Due to Market ‘Uncertainty’2026-09-29 11:48 UTC
Smart Ring Maker Oura Delays IPO Due to Market ‘Uncertainty’2026-09-29 11:48 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Study to Assess the Long-term Safety of KN3835 in the Treatment and Retreatment of Flexible/Semi-Flexible Hammertoe (HMT) — Endo USA Inc., a Keenova Therapeutics Company2026-09-29 12:00 UTC
New Phase 3 trial: Study to Assess the Long-term Safety of KN3835 in the Treatment and Retreatment of Flexible/Semi-Flexible Hammertoe (HMT) — Endo USA Inc., a Keenova Therapeutics Company2026-09-29 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Study of Velaglucerase Beta ERT in Children With Gaucher Disease — CANbridge Life Sciences Ltd.2026-09-29 12:00 UTC
New Phase 3 trial: Study of Velaglucerase Beta ERT in Children With Gaucher Disease — CANbridge Life Sciences Ltd.2026-09-29 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity — Pfizer2026-09-29 12:00 UTC
New Phase 3 trial: A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity — Pfizer2026-09-29 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: A Study to Assess the Efficacy and Safety of Afimkibart for Induction Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — Hoffmann-La Roche2026-09-29 12:00 UTC
New Phase 3 trial: A Study to Assess the Efficacy and Safety of Afimkibart for Induction Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — Hoffmann-La Roche2026-09-29 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer — Seagen Inc.2026-09-29 12:00 UTC
Phase 3 results posted: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer — Seagen Inc.2026-09-29 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.